Orchard licenses the gene therapy technology from GlaxoSmithKline
Orchard Therapeutics has permitted lentiviral stable cell line technology from GlaxoSmithKline for its use in hematopoietic stem cell gene therapies. GSK filed for patents on the tech before selling its rare disease gene therapy portfolio to Orchard in the year 2018.
The use of lentiviral vectors for modification of hematopoietic stem cells outside of the body has resulted in gene therapies, which have shown positive outcomes in people with multiple disorders, including complex genetic diseases. Nevertheless, the complexity of clinical-grade lentiviral vector production has been a barrier to...
